BioSpace News Archive

Emmaus Life Sciences, Inc., a leader in sickle cell disease treatment, announced that APCER Life Sciences has confirmed the safety profile of Endari®, Emmaus’ prescription grade L-glutamine oral powder for the treatment of sickle cell disease.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the first patient was dosed in Cohort 4 of the ongoing OPTIC Phase 1 clinical trial for ADVM-022 for the treatment of wet age-related macular degeneration (AMD). Patients in Cohort

Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of Jonathan Freve, CPA, as its Chief Financial Officer (CFO).

In response to the global COVID-19 pandemic, Erba Mannheim announced the development and imminent launch of its ErbaLisa® COVID-19 ELISA kits for detection of IgG and IgM antibodies to SARS-CoV-2.

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today presented the early clinical data on CG-806, the company’s oral, first-in-class FLT3/BTK cluster selective kinase inhibitor, at the AACR Virtual Annual Meeting I (April 27-28), in lieu of the live oral presentation originally planned. Rafael Bejar M.D., Ph.D.,

BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that its 2020 Annual Meeting of Stockholders will be held virtually, moving away from an in-person event due to the evolving nature of the COVID-19 pandemic. Virtual meeting date: Friday, May 8, 2020 Virtual meeting time: 8:30 a.m. EDT Virtual meetin

Exclusive Partnership Extends Reach of Surgical Wound Closure Innovation, Eliminates In-Office Removal Requirements

Virscio, a translational research company providing definitive, actionable preclinical outcomes through the use of predictive, validated disease models, today announced publication of data that validate a nonhuman primate (NHP) model for testing drug candidates targeting retinal ischemic and neovascular diseases

Boehringer Ingelheim Animal Health announced the appointment of Randolph Legg as the new Head of U.S. Commercial Business.

SGX-listed Singapore eDevelopment Ltd’s (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc., announced today that their suite of antiviral and medical technologies, co-owned with its partners, is valued at USD 592 Million (SGD 841 Million)